Lipid nanoparticles to counteract gastric infection without affecting gut microbiota

Seabra, Catarina Leal; Nunes, Cláudia; Brás, M. Manuela; Gómez-Lázaro, María; Reis, Celso A.; Gonçalves, Inês C.; Reis, Salette; Martins, M. Cristina L.

doi:10.1016/j.ejpb.2018.02.030

Cited by 34 publications

(31 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Focus has been given to understanding bacterial infection mechanisms and interaction with the host [19,20], identifying bacterial specific molecules that may represent potential targets, such as bacterial virulence factors, urease, flagella or surface adhesins [21][22][23]. The combination of these targets with improved encapsulation systems for local delivery of antibiotics (using micro-or nano-systems) [24][25][26][27][28][29][30][31][32][33], usage of compounds from natural sources [34][35][36][37][38][39][40][41] or vaccination [42][43][44][45] has allowed the development of more precise and efficient systems aiming H. pylori eradication.…”

Section: Introductionmentioning

confidence: 99%

Orally administrated chitosan microspheres bind Helicobacter pylori and decrease gastric infection in mice

et al. 2020

Self Cite

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Section: Introductionmentioning

confidence: 99%

Orally administrated chitosan microspheres bind Helicobacter pylori and decrease gastric infection in mice

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…The antibacterial effect of empty LipoSC-MELB4 was speculated to be induced by liposome–bacterial membrane fusion as proposed previously. 50 However, this concentration was approximately 800 times greater than that of LipoSC-MELB4/AMX. Thus, at the same concentrations as low as those of LipoSC-MELB4/AMX, the antibacterial contribution from empty LipoSC-MELB4 was negligible.…”

Section: Resultsmentioning

confidence: 87%

Cosmetic-Derived Mannosylerythritol Lipid-B-Phospholipid Nanoliposome: An Acid-Stabilized Carrier for Efficient Gastromucosal Delivery of Amoxicillin for In Vivo Treatment of Helicobacter pylori

Geng

Cheng

et al. 2022

ACS Omega

View full text Add to dashboard Cite

Helicobacter pylori infection is a leading cause of gastritis and peptic ulcer. Current treatments for H. pylori are limited by the increase in antibiotic-resistant strains and low drug delivery to the infection site, indicating the need for effective delivery systems of antibiotics. Although liposomes are the most successful drug delivery carriers that have already been applied commercially, their acidic stability still stands as a problem. Herein, we developed a novel nanoliposome using cosmetic raw materials of mannosylerythritol lipid-B (MEL-B), soy bean lecithin, and cholesterol, namely, LipoSC-MELB. LipoSC-MELB exhibited enhanced stability under the simulated gastric-acid condition, owing to its strong intermolecular hydrogen-bond interactions caused by the incorporation of MEL-B. Moreover, amoxicillin-loaded LipoSC-MELB (LipoSC-MELB/AMX) had a particle size of approximately 100 nm and exhibited sustained drug release under varying pH conditions (pH 3–7). Besides, LipoSC-MELB/AMX exhibited significantly higher anti- H. pylori and anti- H. pylori biofilm activity as compared with free AMX. Furthermore, LipoSC-MELB was able to carry AMX across the barriers of gastric mucus and H. pylori biofilms. Remarkably, in vivo assays indicated that LipoSC-MELB/AMX was effective in treating H. pylori infection and its associated gastritis and gastric ulcers. Overall, the findings of this study showed that LipoSC-MELB was effective for gastromucosal delivery of amoxicillin to improve its bioavailability for the treatment of H. pylori infection.

show abstract

“…(2017) Se NPs (unknown size) In vitro static culture at a concentration of 0.9 mg/kg Significant reduction in the abundance of pathogenic E. cecorum without significant disturbance to the total GM community 2 Gangadoo et al. (2019) Nanostructured lipid carriers (NLC, 211 nm) In vitro static culture, 0, 1.25, 2.5 and 5% v/v This selective eradication of H. pylori without affecting the other tested human GM 3 Seabra et al. (2018) Ag NPs (11 nm), PVP-capped Cultured GM from human stool exposed NPs at 0, 25, 100 and 200 mg/L Reduction in gas production as well as changes in fatty acid methyl ester profiles 2 Das et al.…”

Section: Resultsmentioning

confidence: 99%

A systematic review on the effects of nanomaterials on gut microbiota

Utembe

Tlotleng

Kamng’ona

2022

Current Research in Microbial Sciences

View full text Add to dashboard Cite

Lipid nanoparticles to counteract gastric infection without affecting gut microbiota

Cited by 34 publications

References 40 publications

Orally administrated chitosan microspheres bind Helicobacter pylori and decrease gastric infection in mice

Orally administrated chitosan microspheres bind Helicobacter pylori and decrease gastric infection in mice

Cosmetic-Derived Mannosylerythritol Lipid-B-Phospholipid Nanoliposome: An Acid-Stabilized Carrier for Efficient Gastromucosal Delivery of Amoxicillin for In Vivo Treatment of Helicobacter pylori

A systematic review on the effects of nanomaterials on gut microbiota

Contact Info

Product

Resources

About